AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Sponsored Reports
Loading...
| Previous Close (in USD) | 2.96 |
|---|---|
| Change | +0.040 1.351% |
| 52 W H/L (in USD) | 7.340/2.630 |
| EBITDA (in USD) | -10.557M |
| PE Ratio | -- |
| Volume | 868396 |
| Diluted Eps TTM | -- |
| Total Assets (in USD) | 226.798M |
|---|---|
| Total Liabilities (in USD) | 504.659M |
| Revenue TTM (in USD) | 114.196M |
| Cash (in USD) | 2.998M |
| Market Cap (in USD) | 150.138 M |
| Revenue Per Share TTM | 3.841 |
| Gross Profit TTM (in USD) | 110.223M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Agenus Inc
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Employees: 81
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Garo H. Armen Ph.D. | Founder, Exec. Chairman & CEO | 1953 |
| 2. | Ms. Christine M. Klaskin | VP of Fin., Principal Financial Officer & Principal Accounting Officer | 1966 |
| 3. | Dr. Steven J. O'Day M.D., Ph.D. | Chief Medical Officer | 1962 |
| 4. | Dr. Jennifer S. Buell Ph.D. | Pres & CEO of MiNK Therapeutics | 1975 |
| 5. | Craig Winter | Chief Information Officer | NA |
| 6. | Regina Grebla Ph.D. | VP of Investor Relations & Communications | NA |
| 7. | Ms. Robin E. Abrams J.D. | Chief Legal Officer | 1964 |
| 8. | Ms. Tracy Mazza Clemente | Chief People Officer | NA |
| 9. | John Castle | Head of Translational Medicine & Bioinformatics | NA |
| 10. | Ms. Julie DeSander | Chief Bus. Officer | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.330 0.758% | 43.45 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
0.000 0.000% | 43 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-7.360 1.604% | 462.17 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+2.010 0.331% | 612.07 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Income Before Tax | -3.083M | -232.271M | -257.437M | -230.656M | -28.724M |
| Minority Interest | 3.198M | 5.059M | 12.393M | -10.582M | -4.798M |
| Net Income | 0.115M | -227.212M | -245.761M | -271.515M | -94.696M |
| Selling General Administrative | 54.392M | 71.878M | 78.739M | 81.007M | 76.359M |
| Gross Profit | 103.175M | -52.551M | -81.366M | -99.235M | 113.587M |
| Reconciled Depreciation | 9.999M | 13.343M | 10.276M | 6.946M | 6.788M |
| Ebit | -20.556M | -114.645M | -159.512M | -179.427M | 42.279M |
| Ebitda | -10.557M | -101.302M | -145.924M | -160.725M | 49.067M |
| Depreciation And Amortization | 9.999M | 13.343M | 13.588M | 18.702M | 6.788M |
| Operating Income | -20.556M | -120.475M | -159.549M | -179.427M | 42.279M |
| Other Operating Expenses | 134.752M | 223.938M | 315.863M | 278.266M | 258.437M |
| Interest Expense | 55.618M | 117.626M | 97.925M | 61.863M | 65.719M |
| Tax Provision | - | - | - | - | - |
| Interest Income | - | - | - | - | - |
| Net Interest Income | -55.273M | -117.626M | -71.07M | -61.863M | -65.719M |
| Income Tax Expense | - | - | -11.676M | 40.859M | 65.972M |
| Total Revenue | 114.196M | 103.463M | 156.314M | 98.024M | 295.665M |
| Total Operating Expenses | 123.731M | 67.924M | 78.183M | 81.007M | 76.359M |
| Cost Of Revenue | 11.021M | 156.014M | 237.68M | 197.259M | 182.078M |
| Total Other Income Expense Net | 17.473M | -111.796M | -97.888M | -51.229M | -71.003M |
| Net Income From Continuing Ops | -3.083M | -232.271M | -282.957M | -228.719M | -28.724M |
| Net Income Applicable To Common Shares | - | - | - | -220.286M | -24.137M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Total Assets | 226.798M | 226.271M | 313.913M | 413.556M | 465.958M |
| Intangible Assets | 3.037M | 3.376M | 4.411M | 6.228M | 8.488M |
| Other Current Assets | 128.607M | 4.73M | 10.47M | 3.194M | 3.171M |
| Total Liab | 504.659M | 532.695M | 462.295M | 468.458M | 418.049M |
| Total Stockholder Equity | -271.111M | -326.38M | -160.331M | -61.278M | 34.44M |
| Other Current Liab | 83.109M | 150.054M | 48.741M | 133.226M | 110.677M |
| Common Stock | 0.353M | 0.236M | 3.944M | 3.056M | 2.569M |
| Capital Stock | 0.353M | 0.236M | 3.944M | 3.056M | 2.569M |
| Retained Earnings | -2182.765M | -2182.88M | -1955.668M | -1709.907M | -1489.833M |
| Good Will | 24.092M | 24.092M | 24.723M | 25.467M | 24.876M |
| Other Assets | - | - | - | 4.453M | 9.537M |
| Cash | 2.998M | 40.437M | 76.11M | 178.674M | 291.931M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 323.489M | 221.401M | 255.897M | 188.952M | 156.943M |
| Current Deferred Revenue | 1.143M | 0.031M | 0.018M | 12.269M | 12.425M |
| Net Debt | 331.901M | 54.433M | 274.136M | -100.246M | -233.644M |
| Short Term Debt | 156.25M | 9.846M | 145.692M | 2.518M | 3.355M |
| Short Long Term Debt | 44.655M | 2.698M | 0.146M | 0.575M | 0.728M |
| Short Long Term Debt Total | 334.899M | 94.87M | 350.246M | 78.428M | 58.287M |
| Other Stockholder Equity | 1911.74M | 1857.662M | 1478.435M | 1231.102M | 1054.254M |
| Property Plant Equipment | - | - | - | 133.017M | 91.083M |
| Total Current Assets | 133.436M | 45.574M | 112.416M | 213.122M | 331.974M |
| Long Term Investments | 24.277M | 0M | - | - | - |
| Short Term Investments | - | - | 0M | 14.684M | 14.992M |
| Net Receivables | 1.831M | 0.407M | 25.836M | 2.741M | 1.518M |
| Long Term Debt | - | 30.473M | 12.768M | 12.584M | 12.823M |
| Inventory | - | - | 0M | 13.829M | 20.362M |
| Accounts Payable | 82.987M | 61.47M | 61.446M | 40.939M | 30.486M |
| Accumulated Other Comprehensive Income | -0.439M | -1.398M | -0.955M | 0.915M | 1.492M |
| Non Currrent Assets Other | -0.742M | 5.834M | 5.667M | 4.453M | 9.537M |
| Non Current Assets Total | 93.362M | 180.697M | 201.497M | 200.434M | 133.984M |
| Capital Lease Obligations | 11.244M | 61.699M | 65.098M | 65.269M | 44.736M |
| Long Term Debt Total | - | - | - | 12.584M | 12.823M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Investments | 0.841M | 0.027M | 3.4M | 0.371M | -14.992M |
| Total Cashflows From Investing Activities | 0.027M | 0.027M | 3.4M | -33.61M | -43.15M |
| Total Cash From Financing Activities | 122.84M | 122.84M | 119.866M | 95.83M | 225.264M |
| Net Income | -232.271M | -232.271M | -257.437M | -230.656M | -28.724M |
| Change In Cash | -35.708M | -35.708M | -101.564M | -113.257M | 192.095M |
| Begin Period Cash Flow | 79.779M | 79.779M | 181.343M | 294.6M | 102.505M |
| End Period Cash Flow | 44.071M | 44.071M | 79.779M | 181.343M | 294.6M |
| Total Cash From Operating Activities | -158.315M | -158.315M | -224.202M | -175.373M | 10.145M |
| Depreciation | 13.343M | 13.343M | 13.588M | 6.946M | 6.788M |
| Other Cashflows From Investing Activities | 0.024M | 0.024M | 3.363M | 19.081M | 5.656M |
| Dividends Paid | - | - | - | - | -9.132M |
| Change To Inventory | - | - | - | - | -6.191M |
| Sale Purchase Of Stock | -0.087M | 0M | -5.172M | -3.789M | -1.654M |
| Other Cashflows From Financing Activities | 84.273M | 74.498M | 0.807M | 0.898M | 16.722M |
| Capital Expenditures | 0.576M | 0.576M | 9.954M | 53.062M | 33.814M |
| Change In Working Capital | 27.334M | 32.604M | 10.756M | 24.084M | -9.743M |
| Other Non Cash Items | 15.889M | 10.619M | -13.978M | 5.916M | 31.745M |
| Free Cash Flow | -158.891M | -158.891M | -234.156M | -228.435M | -23.669M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | iShares Micro-Cap ETF | 2 months ago | 80823 |
| 2. | Extended Equity Market Fund K | 2 months ago | 71442 |
| 3. | Fidelity Total Market Index | 3 months ago | 60552 |
| 4. | Vanguard Total Stock Mkt Idx Inv | 2 months ago | 1022172 |
| 5. | Vanguard Strategic Equity Inv | 5 months ago | 511809 |
| 6. | Vanguard Institutional Extnd Mkt Idx Tr | 2 months ago | 386794 |
| 7. | Vanguard Explorer Inv | 5 months ago | 290646 |
| 8. | Vanguard Strategic Small-Cap Equity Inv | 5 months ago | 205345 |
| 9. | Vanguard VIF Small Co Gr | 5 months ago | 197612 |
| 10. | Fidelity Extended Market Index | 3 months ago | 131029 |
| 11. | Acuitas US Microcap Strategy | 5 months ago | 122160 |
| 12. | Blackrock Extended Mkt Fund CF | 3 months ago | 83905 |
| 13. | Extended Equity Market Fund B | 5 months ago | 83905 |
| 14. | Extended Equity Market Fund E | 5 months ago | 83905 |
| 15. | Spartan Extended Market Index Pool F | 3 months ago | 47894 |
| 16. | Fidelity Series Total Market Index | 3 months ago | 47743 |
| 17. | NT Ext Equity Mkt Idx Fd - L | 2 months ago | 40461 |
| 18. | Vanguard Market Neutral I | 4 months ago | 33574 |
| 19. | Northern Trust Extended Eq Market Idx | 8 months ago | 32386 |
| 20. | Dasc Investments SICAV | 11 months ago | 29897 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Renaissance Technologies Corp | 5 months ago | 543546 |
| 2. | Citadel Advisors Llc | 5 months ago | 423242 |
| 3. | Geode Capital Management, LLC | 5 months ago | 372748 |
| 4. | Bank of America Corp | 8 months ago | 369314 |
| 5. | Vanguard Group Inc | 5 months ago | 2830736 |
| 6. | Siren, L.L.C. | 5 months ago | 1064250 |
| 7. | Morgan Stanley - Brokerage Accounts | 8 months ago | 549126 |
| 8. | BlackRock Inc | 8 months ago | 547112 |
| 9. | Susquehanna International Group, LLP | 5 months ago | 233674 |
| 10. | Millennium Management LLC | 5 months ago | 225339 |
| 11. | Jump Financial LLC | 5 months ago | 170407 |
| 12. | Panagora Asset Management Inc | 5 months ago | 163148 |
| 13. | State Street Corp | 8 months ago | 150583 |
| 14. | Marshall Wace Asset Management Ltd | 5 months ago | 146800 |
| 15. | D. E. Shaw & Co LP | 5 months ago | 127638 |
| 16. | Walleye Trading Advisors, LLC | 5 months ago | 123458 |
| 17. | Two Sigma Investments LLC | 5 months ago | 117117 |
| 18. | 683 Capital Management LLC | 5 months ago | 114336 |
| 19. | Man Group PLC | 5 months ago | 114204 |
| 20. | Point72 Asset Management, L.P. | 5 months ago | 108220 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...